miR-4770 promotes colorectal cancer progression by targeting PRKAA2 via m6A modification

Figure 1 The regulation of METTL3 on miR-4770 expression and N6-methyladenosine modification level. A: The expression of METTL3 in colorectal cancer (CRC) tissues and normal tissues was detected by qRT-PCR; B: The expression of miR-4770 was positively correlated with METTL3 in CRC tissues; C-E: The expression of METTL3 (C), miR-4770 (D) and pri-miR-4770 (E) was detected in siNC, si-METTL3, NC and METTL3-oe cells (qRT-PCR); F: RIP assay was used to detect the binding level of pri-miR-4770 and DGCR8 in the above four groups of cells; G: MeRIP assay was used to detect the N6-methyladenosine modification level of pri-miR-4770 in the above four groups of cells. Data were expressed as mean ± SD. ^aP < 0.01 vs normal group; ^bP < 0.05 and ^cP < 0.01 vs siNC group; ^dP < 0.01 vs NC group. Clinical tissue analyses were based on 10 paired CRC and adjacent normal tissues, whereas in vitro experiments were performed with three independent biological replicates. CRC: Colorectal cancer.